# Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

> **NCT07132008** · PHASE3 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 94 (estimated)

## Conditions studied

- Colonic Neoplasms
- Neoadjuvant Therapy
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07132008
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132008, "Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07132008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*